Bright Minds Biosciences Inc. Common Stock
Symbol: DRUG (NASDAQ)
42.00
▼ (-0.40%) -0.170
Company Description:
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Key Stats
- Today's Open: $42
- Today's High: $42.76
- Today's Low: $41.42
- Today's Volume: 87.25K
- Yesterday Close: $42.17
- Yesterday High: $42.99
- Yesterday Low: $39.6968
- Yesterday Volume: 106.72K
- Last Min Volume: 1
- Last Min High: $42
- Last Min Low: $42
- Last Min VWAP: $42
Company Profile
- Name: Bright Minds Biosciences Inc. Common Stock
- Website: https://www.brightmindsbio.com
- Listed Date: 2021-03-08
- Location: ,
- Market Status: Active
- CIK Number: 0001827401
- SIC Code:
- SIC description:
- Market Cap: $304.60M
- Round Lot: 100
- Outstanding Shares: 7.09M
- Asset Type: CS
RECENT FILINGS FOR DRUG
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-05 | 6-K | View |
| 2025-09-02 | EFFECT | View |
| 2025-08-26 | F-3 | View |
| 2025-08-15 | 6-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-13 | SCHEDULE 13G/A | View |
| 2025-08-11 | 6-K | View |
| 2025-05-28 | 6-K | View |
| 2025-05-21 | 6-K | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-14 | 6-K | View |
| 2025-04-29 | 6-K | View |
| 2025-04-08 | SCHEDULE 13G | View |
| 2025-04-07 | SCHEDULE 13G/A | View |
| 2025-03-05 | 6-K | View |
| 2025-02-24 | 6-K | View |
| 2025-02-14 | EFFECT | View |
| 2025-02-14 | 424B3 | View |
| 2025-02-14 | SCHEDULE 13G/A | View |
Latest News on DRUG